Table 4

Estimated change in cognitive function by follow-up time point and according to drug groups and municipality groups*
Estimated change (95% CI) versus baseline at p-values
Groups 4 months 8 months, 12 months P1 P2
MMSE
Drug groups
Placebo −0.402 (−0.988, 0.185) −0.015 (−0.584, 0.553) −0.335 (−1.046, 0.375) 0.208 0.284
Donepezil 0.145 (−0.440, 0.730) 0.411 (−0.166, 0.988) −0.470 (−1.181, 0.241)
Municipality groups
Standard care 0.198 (−0.429, 0.826) 0.790 ( 0.190, 1.389) 0.156 (−0.588, 0.901) 0.017 0.508
Stimulation −0.380 (−0.933, 0.172) −0.272 (−0.807, 0.262) −0.841 (−1.510, -0.172)
Clock Drawing Test
Drug groups
Placebo 0.103 (−0.081, 0.288) 0.124 (−0.082, 0.330) 0.134 (−0.079, 0.347) 0.264 0.570
Donepezil −0.016 (−0.200, 0.169) −0.101 (−0.309, 0.107) 0.031 (−0.183, 0.245)
Municipality groups
Standard care 0.120 (−0.076, 0.317) 0.210 (−0.008, 0.428) 0.234 ( 0.011, 0.456) 0.071 0.257
Stimulation −0.017 (−0.191, 0.158) −0.144 (−0.339, 0.050) −0.038 (−0.242, 0.165)
ADAS-cog
Drug groups
Placebo −0.383 (−1.412, 0.646) −1.126 (−2.201, -0.051) −0.492 (−1.635, 0.650) 0.235 0.886
Donepezil −1.027 (−2.053, -0.001) −1.948 (−3.033, -0.862) −1.510 (−2.661, -0.359)
Municipality groups
Standard care −1.515 (−2.597, -0.433) −1.736 (−2.889, -0.582) −1.619 (−2.830, -0.407) 0.108 0.242
Stimulation −0.069 (−1.030, 0.893) −1.380 (−2.407, -0.352) −0.493 (−1.590, 0.603)

* Linear mixed models adjusted for baseline cognitive score.

P1, p-value for overall equality of change between the groups.

P2, p-value for test of interaction between group and time, i.e. test for constant differences between groups over time.

Andersen et al.

Andersen et al. BMC Neurology 2012 12:59   doi:10.1186/1471-2377-12-59

Open Data